Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?

The article discusses the role of fingolimod (FTY) in inducing lymphopenia in multiple sclerosis(MS) patients and implications post withdrawal of FTY. It refers to a study in which a patient developed a rebound syndrome within four weeks post cessation of the drug, characterized by hemiparesis and imbalance of gait. It suggests clinicians should systematically collect and examine laboratory and imaging data to understand the risks of prolonged lymphopenia during FTY use in MS.